Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species

Toxicology and Applied Pharmacology

Volumn 207, Issue 2 SUPPL., 2005, Pages 354-366

  Wells, Peter G ^a,b   Bhuller, Yadvinder ^a,c   Chen, Connie S ^a,d   Jeng, Winnie ^a,e   Kasapinovic, Sonja ^a,f   Kennedy, Julia C ^a,g   Kim, Perry M ^a,h   Laposa, Rebecca R ^a,i   McCallum, Gordon P ^a   Nicol, Christopher J ^b,j   Parman, Toufan ^a,k   Wiley, Michael J ^b   Wong, Andrea W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HEALTH CANADA   (Canada)

^d Loewen Ondaatje and McCutcheon Ltd   (Canada)

^e UK   (United States)

^f TORONTO GENERAL HOSPITAL   (Canada)

^g HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^h Parteq Inc   (Canada)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j QUEEN S UNIVERSITY   (Canada)

^k SRI INTERNATIONAL   (United States)

more..

Author keywords

Prostaglandin H synthase; Reactive oxygen species; Teratogen

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ALPHA TOCOPHEROL; ANTIOXIDANT; BENZO[A]PYRENE; CAFFEIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHEMICAL TERATOGEN; CYTOCHROME P450 INHIBITOR; DEFEROXAMINE; DIMETHADIONE; GLUTATHIONE; ICOSATETRAENOIC ACID; INDOMETACIN; LIPOXYGENASE; MEPHENYTOIN; METHAMPHETAMINE; N TERT BUTYL ALPHA PHENYLNITRONE; NITRIC OXIDE SYNTHASE INHIBITOR; NORMEPHENYTOIN; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; REACTIVE OXYGEN METABOLITE; THALIDOMIDE; TRIMETHADIONE; XENOBIOTIC AGENT;

BEHAVIOR DISORDER; BIRTH DEFECT; CANCER; CELL DAMAGE; CELL PROTECTION; CHEMICAL TERATOGENESIS; CONFERENCE PAPER; DEVELOPMENTAL DISORDER; DNA DAMAGE; DNA REPAIR; DRUG SAFETY; EMBRYO CULTURE; EMBRYOPATHY; ENZYME ACTIVATION; EXAMINATION; GAMMA IRRADIATION; GENOTOXICITY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; HYPOTHESIS; INTELLECTUAL IMPAIRMENT; KNOCKOUT MOUSE; LIPID OXIDATION; MACROMOLECULE; MOLECULAR MECHANICS; MOUSE MUTANT; NERVE CELL DIFFERENTIATION; NONHUMAN; OXIDATIVE STRESS; RABBIT; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TERATOGENICITY;

ORYCTOLAGUS CUNICULUS;

EID: 24644492970     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.01.061     Document Type: Conference Paper

References (46)

1. R.R. Arlen, and P.G. Wells Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase-catalysed bioactivation of thalidomide to a teratogenic reactive intermediate J. Pharmacol. Exp. Ther. 277 1996 1649 1658
2. F. Azarbayjani, and B.R. Danielsson Embryonic arrhythmia by inhibition of HERG channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs? Epilepsia 43 2002 457 468
3. C.S. Chen, and P.G. Wells In utero origins of cancer: maternal dietary vitamin E, fetal oxidative DNA damage and postnatal carcinogenesis in p53 knockout mice F. Kelly M. Meydani L. Packer Vitamin E and Health Ann. NY Acad. Sci. vol. 1031 2004 395 398
4. C.S. Chen, and P.G. Wells Enhanced tumorigenesis in p53 knockout mice exposed in utero to high-dose vitamin E Carcinogenesis 2005 (in press)
5. A.G. Fantel Reactive oxygen species in developmental toxicity: review and hypothesis Teratology 53 1996 196 217
6. A.G. Fantel, and R.E. Person Further evidence for the role of free radicals in the limb teratogenicity of l-NAME Teratology 66 2002 24 32
7. B. Halliwell, and L.M.C. Gutteridge Free Radicals in Biology and Medicine 1999 Oxford Univ. Press New York
8. J.M. Hansen, S.-G. Gong, M. Philbert, and C. Harris Misregulation of gene expression by the redox-sensitive NF-kB-dependent limb outgrowth pathway by thalidomide Dev. Dyn. 255 2002 186 194
9. Z. Hu, and P.G. Wells In vitro and in vivo biotransformation and covalent binding of benzo(a)pyrene in rats with a genetic deficiency in bilirubin UDP-glucuronosyltransferase J. Pharmacol. Exp. Ther. 263 1992 334 342
10. W. Jeng, and P.G. Wells Free radical determinants of amphetamine neurodegeneration: prostaglandin H synthase-catalyzed free radical formation and reactive oxygen species-mediated oxidative DNA damage in neuronal degeneration and functional deficits Toxicol. Sci. 78 S-1 2004 413 (No. 2004, [abstract])
11. W. Jeng, A.W. Wong, R. Ting-A-Kee, and P.G. Wells Methamphetamine- enhanced embryonic oxidative DNA damage and neurodevelopmental deficits Free Radical Biol. Med. 39 2005 317 326
12. M.R. Juchau, Q.P. Lee, and A.G. Fantel Xenobiotic biotransformation bioactivation in organogenesis-stage conceptal tissues: implications for embryotoxicity and teratogenesis Drug Metab. Rev. 24 1992 195 238
13. M.R. Juchau, H. Boutelet-Bochan, and Y. Huang Cytochrome P450-dependent biotransformation of xenobiotics in human and rodent embryonic tissues Drug Metab. Rev. 30 1998 541 568
14. S. Kasapinovic, G.P. McCallum, M.J. Wiley, and P.G. Wells The peroxynitrite pathway in development: phenytoin and benzo[a]pyrene embryopathies in inducible nitric oxide synthase (iNOS) knockout mice Free Radical Biol. Med. 37 2004 1703 1711
15. J.C. Kennedy, S. Memet, and P.G. Wells Antisense evidence for nuclear factor kB-dependent embryopathies initiated by phenytoin-enhanced oxidative stress Mol. Pharmacol. 66 2004 404 412
16. P.M. Kim, and P.G. Wells Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene Cancer Res. 56 1996 1526 1532
17. P.M. Kim, and P.G. Wells Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene Cancer Res. 56 1996 1526 1532
18. P.M. Kim, and P.G. Wells Phenytoin-initiated hydroxyl radical formation: characterisation by enhanced salicylate hydroxylation Mol. Pharmacol. 49 1996 172 181
19. P.M. Kim, and P.G. Wells Phenytoin embryotoxicity: protection by UDP-glucuronosyltransferases Toxicol. Sci. 42 1-S 1998 261 (No. 1288, [abstract])
20. P.M. Kim, U. De Boni, and P.G. Wells Peroxidase-dependent bioactivation and oxidation of DNA and protein in benzo[a]pyrene-initiated micronucleus formation Free Radical Biol. Med. 23 1997 579 596
21. P.M. Kim, L.M. Winn, T. Parman, and P.G. Wells UDP- glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH) J. Pharmacol. Exp. Ther. 280 1997 200 209
22. P.M. Kim, L.M. Winn, T. Parman, and P.G. Wells UDP- glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH) J. Pharmacol. Exp. Ther. 280 1997 200 209
23. R.R. Laposa, M.J. Wiley, and P.G. Wells Evidence for non-apoptotic pathways mediating phenytoin teratogenicity in mice Fundam. Appl. Toxicol. 36 S-1 1997 303 (abstract)
24. R.R. Laposa, J.T. Henderson, E. Xu, and P.G. Wells Atm-null mice exhibit enhanced radiation-induced birth defects and a hybrid form of embryonic programmed cell death indicating a teratological suppressor function for ATM FASEB J. 18 2004 896 898 (Full paper: http://www.fasebj.org/cgi/reprint/803- 0903fjev0901?ijkey=OSCR0903bZYu0912k.&keytype=ref&siteid=fasebj)
25. L. Liu, and P.G. Wells DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2′-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues Free Radical Biol. Med. 19 1995 639 648
26. L.J. Marnett Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyl radicals as reactive intermediates Environ. Health Perspect. 88 1990 5 12
27. L.J. Marnett, J.N. Riggins, and J.D. West Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein J. Clin. Invest. 111 2003 583 593
28. C.J. Nicol, M.L. Harrison, R.R. Laposa, I.L. Gimelshtein, and P.G. Wells A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice Nat. Genet. 10 1995 181 187
29. C.J. Nicol, J. Zielenski, L.-C. Tsui, and P.G. Wells An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis FASEB J. 14 2000 111 127
30. T.R.S. Ozolins, D.L.A. Siksay, and P.G. Wells Modulation of embryonic glutathione peroxidase activity and phenytoin teratogenicity by dietary deprivation of selenium in CD-1 mice J. Pharmacol. Exp. Ther. 277 1996 945 953
31. T. Parman, and P.G. Wells Embryonic prostaglandin H synthase-2 (PHS-2) expression and benzo[a]pyrene teratogenicity in PHS-2 knockout mice FASEB J. 16 2002 1001 1009
32. T. Parman, G. Chen, and P.G. Wells Free radical intermediates of phenytoin and related teratogens: prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry and photochemical product analysis J. Biol. Chem. 273 1998 25079 25088
33. T. Parman, M.J. Wiley, and P.G. Wells Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity Nat. Med. 5 1999 582 585
34. M.J. Shanks, M.J. Wiley, S. Kubow, and P.G. Wells Phenytoin teratogenicity: role of enzymatic bioactivation in a murine embryo culture model Teratology 40 1989 311 320
35. P.G. Wells, and L.M. Winn Biochemical toxicology of chemical teratogenesis Crit. Rev. Biochem. Mol. Biol. 31 1996 1 40
36. P.G. Wells, A. Kupfer, J.A. Lawson, and R.D. Harbison Relation of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mice: evaluation of mephenytoin and its metabolite, nirvanol J. Pharmacol. Exp. 1982 221
37. P.G. Wells, M.K. Nagai, and G. Spano Greco Inhibition of trimethadione and dimethadione teratogenicity by the cyclooxygenase inhibitor acetylsalicylic acid: a unifying hypothesis for the teratologic effects of hydantoin anticonvulsants and structurally related compounds Toxicol. Appl. Pharmacol. 97 1989 406 414
38. P.G. Wells, P.M. Kim, R.R. Laposa, C.J. Nicol, T. Parman, and L.M. Winn Oxidative damage and teratogenesis Mutat. Res. 396 1997 65 78
39. P.G. Wells, P.M. Kim, C.J. Nicol, T. Parman, and L.M. Winn Chapter 17. Reactive intermediates R.J. Kavlock G.P. Daston Drug Toxicity in Embryonic Development 1997 Springer-Verlag Heidelberg 453 518
40. P.G. Wells, P.I. Mackenzie, J. Roy Chowdhury, C. Guillemette, P.A. Gregory, Y. Ishii, A.J. Hansen, F.K. Kessler, P.M. Kim, N. Roy Chowdhury, and J.K. Ritter Glucuronidation and the UDP-glucuronosyltransferases in drug therapy and disease Drug Metab. Dispos. 32 2004 281 290
41. L.M. Winn, and P.G. Wells Free radical-mediated mechanisms of anticonvulsant teratogenicity Eur. J. Neurol. 2 1995 5 29
42. L.M. Winn, and P.G. Wells Evidence for embryonic prostaglandin H synthase-catalysed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis Free Radical Biol. Med. 22 1997 607 621
43. L.M. Winn, and P.G. Wells Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity Free Radical Biol. Med. 26 1999 266 274
44. L.M. Winn, and P.G. Wells Evidence for Ras-dependent signal transduction in phenytoin teratogenicity Toxicol. Appl. Pharmacol. 184 2002 144 152
45. A.W. Wong, W. Jeng, and P.G. Wells Methamphetamine-initiated neurodevelopmental deficits are enhanced in oxoguanine glycosylase-1 (ogg1) knockout mice Toxicol. Sci. 78 S-1 2004 380 (No. 1843, [abstract])
46. W.K. Yu, and P.G. Wells Evidence for lipoxygenase-catalyzed bioactivation of phenytoin to a teratogenic reactive intermediate: in vitro studies using linoleic acid-dependent soybean lipoxygenase, and in vivo studies using pregnant CD-1 mice Toxicol. Appl. Pharmacol. 131 1995 1 12